Castle Creek Pharmaceuticals

Advanced investigational therapies for the treatment of multiple types of EB

Castle Creek Pharmaceuticals is proud to be a sponsor of EB2020. Congratulations to the organizers for planning and executing this ground-breaking conference.

Castle Creek Pharmaceuticals is a privately held biopharmaceutical company developing innovative therapies for patients living with rare, serious or debilitating dermatologic conditions. The company is dedicated to developing and bringing novel therapies to those living with epidermolysis bullosa. Castle Creek is a portfolio company of Paragon Biosciences, based in Chicago. (paragonbiosci.com)

On September 12, 2019, it was announced that Castle Creek reached an agreement to acquire Fibrocell Science, Inc, a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases.

Both companies have advanced investigational therapies for the treatment of multiple types of EB into late-stage clinical research including recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa simplex (EBS).